IL-12 RB1 Genetic Variants Contribute to Human Susceptibility to Severe Acute Respiratory Syndrome Infection among Chinese

Fang Tang1*, Wei Liu2*, Fang Zhang1, Zhong-Tao Xin2, Mao-Ti Wei3, Pan-He Zhang2, Hong Yang1, Hinh Ly3, Wu-Chun Cao1,2*

1 Beijing Institute of Microbiology and Epidemiology, Beijing, People’s Republic of China, 2 State Key Laboratory of Pathogen and Biosecurity, Beijing, People’s Republic of China, 3 Pathology and Laboratory Medicine Department, Emory University School of Medicine, Atlanta, Georgia, United States of America, 4 Affiliated Hospital of APFCP Medical College, Tianjin, People’s Republic of China

Abstract

Background: Cytokines play important roles in antiviral action. We examined whether polymorphisms of interleukin (IL)-12 receptor β1 (IL-12RB1) affect the susceptibility to and outcome of severe acute respiratory syndrome (SARS).

Methods: A case-control study was carried out in Chinese SARS patients and healthy controls. The genotypes of 4SNPs on IL-12 RB1 gene, +705A/G, +1158T/C, +1196G/C and +1664 C/T, were determined by PCR-RFLP. Haplotypes were estimated from the genotype data using the expectation-maximisation algorithm.

Results: Comparison between patients and close contacts showed that individuals with the +1664 C/T (CT and TT) genotype had a 2.09-fold (95% confidence interval [CI], 1.90–7.16) and 2.34-fold (95% CI, 1.79–13.37) increased risk of developing SARS, respectively. For any of the other three polymorphisms, however, no significant difference can be detected in allele or genotype frequencies between patients and controls. Additionally, estimation of the frequencies of multiple-locus haplotypes revealed potential risk haplotypes (GCCCT) for SARS infection.

Conclusions: Our data indicate that genetic variants of IL12RB1 confer genetic susceptibility to SARS infection, but not necessary associated with the progression of the disease in Chinese population.

Introduction

Severe acute respiratory syndrome (SARS) is an infectious disease caused by the SARS coronavirus with >8000 cases and 774 deaths reported in 2003 [1]. Much progress has been made in understanding the SARS coronavirus, but its pathogenesis in infected individuals remains unclear [2]. The early reports showed that old age, diabetes mellitus and heart disease were risk factors for adverse prognosis of SARS [3,4]. Genetic host factors are as well supposed to play an important role, and polymorphisms in several genes have been tested for their association with the infection [5–13]. Three studies have investigated role of angiotensin converting enzyme gene in disease pathogenesis or disease outcome with conflicting results [5–7]. Two independent studies displayed the significant role of the mannose-binding lectin (MBL) genetic polymorphisms in SARS infection [8,9]. Other candidate genes, such as OAS1 and MxA gene [10], interferon gamma gene [11] and RANTES gene [12], ICAM3 gene [13] were also identified in recent studies. A better understanding of these genes will provide new insights into the disease pathogenesis. This knowledge will also aid in identifying the biomarkers for evaluating the efficacy of vaccination and other interventions.

Interleukin-12 (IL-12) is a cytokine secreted by activated phagocytes and dendritic cells [14]. It plays a pivotal role in promoting Th1-type immune responses and cell-mediated immunity. IL-12 triggers many biological functions: it stimulates the proliferation of activated T- and NK-cells, enhances T- and NK-cell-mediated cytolitic activity, and induces the production of IFN-γ by both T- and NK-cells [Trinchieri 1998]. The interferon-γ production induced by IL-12 forms a major link between innate and adaptive immunity [15]. A recent study revealed that interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in SARS patients [16]. We thus reasoned that IL-12 might also play a role in resistance to SARS, which is signaled through the direct binding of the IL-12 molecule to its receptor (IL-12R). IL-12R has been
shown to consist of at least two distinct subunits, B1 and B2, that associate to form a high-affinity IL-12R complex expressed on activated T- and NK-cells (17,18). In the current study, we hypothesized that polymorphisms of the IL-12R B1 gene might be associated with SARS susceptibility. To test this hypothesis, we conducted a case control study to investigate the association between IL-12R B1 genetic polymorphisms and SARS in Chinese individuals.

Materials and Methods

Cases and controls

The case and controls were selected from two designated hospitals for SARS in Beijing and Tianjin. During the 2003 SARS epidemic, a total of 132 confirmed SARS patients were reported from these two hospitals, which derived from two completely unrelated super spread events (SSE). All of the patients had been hospitalized for treatment, from which we selected 115 confirmed SARS cases for the study. Three of the remaining patients died and the other 14 patients were unavailable for study, because of the inconvenience of revisiting. The diagnosis was made according to the criteria published by the Chinese Ministry of Public Health, and subsequently confirmed by antibody seroconversion and/or detectable SARS-CoV RNA in respiratory secretions. Two control groups were used, individuals with close contacts with SARS patients (control A) and healthy controls (control B). Control A group consists of 141 subjects who had close contacts with confirmed SARS patients but were not infected, according to criteria that was defined by the World Health Organization [19]. Among these individuals were 110 high-risk health care workers who had been treating SARS patients for a prolonged duration, and 31 individuals who had shared a meal, utensil, residence, ward, vehicle, etc., with SARS patients. Control B group included 155 healthy, unrelated Chinese blood donors, who had blood drawn during July 2001–October 2002. All controls were tested negative for IgG antibody against SARS-CoV prior to being included into the study. All subjects contributed 3ml anti-coagulated blood after written informed consent was obtained. We also used a standard questionnaire to collect demographic information (including age, ethnicity, region of origin, marital status, living environment, education level etc). All subjects were compared, and odds ratios (OR) were calculated for control B group. 46.7% of SARS patients, 32.5% of control A group and 71% of control B group were male. Sixty-two SARS cases, 31.6±6.8 years for control A group and 28.4±13.4 years for control B group. The remaining 76 patients were classified as a mild group (mean±SD age = 39.45±12.8, 20 male and 19 female). The remaining 76 patients were classified as a severe group, based on their admissions to intensive care units or deaths due to the disease (mean±SD age = 39.45±12.8, 20 male and 19 female).

Statistical analysis

Genotype distributions of each SNPs were tested for the Hardy–Weinberg equilibrium by the Chi square test in three groups. The genotype frequencies of the SARS patients and the control subjects were compared, and odds ratios (OR) were calculated by assigning the reference value (1.0) to the homozygous genotype that was more frequent in the control subjects than in the SARS patients. The OR and P values were calculated by multivariate logistic regression analysis with age, sex, comorbidity presence and infection source entered as covariates in the model, given the relevance of these potential confounding variables in interpreting the study results. Data were analyzed using the SPSS software (version 10.0, SPSS Inc, Chicago, IL, USA). To correct for multiple testing, we used spectral decomposition (SpD) of matrices of pairwise linkage disequilibrium (LD) between SNPs, which adjusts for multiple testing while taking into account LD among the tested SNPs [21]. This method showed that P-values of 0.0227 and below can be considered as statistically significant after correction for multiple testing. The software HAPLOVIEW (version 2.05) was used to construct haplotypes from the genotype data. This program calculates association statistics for multilocus haplotypes in case-control data using the expectation- maximisation algorithm to estimate haplotype odds ratios across multiple categories, giving a likelihood ratio test of homogeneity.

Results

Baseline Clinical Characteristics of cases and controls

Table 1 shows the baseline characteristics of SARS patients and two control groups. The mean age was 33.1±11.7 years for SARS cases, 31.6±7.0 years for control A group and 28.4±11.8 years for control B group. 46.7% of SARS patients, 32.5% of control A group and 71% of control B group were male. Sixty-two SARS patients were health care workers. Thirty-nine (33.9%) patients were classified as a severe group, based on their admissions to intensive care units or deaths due to the disease (mean±SD age = 39.45±12.8, 20 male and 19 female). The remaining 76 patients were classified as a mild group (mean±SD age = 29.61±13.5, 46 male and 36 female).
Genotype Frequencies of the 4 SNPs of the IL12RB1 gene in SARS Patients and Controls

The Hardy-Weinberg equilibrium test based on the genotype frequency was carried out separately for the three groups of individuals. For control B group, the genotype distributions of the 4 SNPs (+1664 C/T, +1158 T/C, +1196 G/C and +1664 C/T) were in Hardy-Weinberg equilibrium, while for patients group, the genotype distribution of +1664 C/T polymorphisms deviate slightly from Hardy-Weinberg equilibrium (data not shown). The genotyping results were missing from some of the patients, because the DNA samples were not enough for all of the loci detection, or the poor RFLP results, which led to their exclusion because the DNA samples were not enough for all of the loci detection, or the poor RFLP results, which led to their exclusion. Allele frequencies at the four loci were +705 A/G, +1158 T/C, +1196 G/C and +1664 C/T polymorphisms deviate slightly from Hardy-Weinberg equilibrium (data not shown).

Genotype frequencies at four loci are shown in Table 3. A significant difference in the genotype frequencies between SARS patients and controls was found for the +1664 C/T SNPs (P < 0.001). The +1664 C/T (CT) and (TT) genotypes were significantly over represented in patients (41.5% and 8.5%, respectively) than in control A group (29.5% and 4.5%, respectively). Compared to the CC genotype, CT and TT genotypes were found to be associated with increased susceptibility to SARS infection with ORs (95% CI) of 2.09 (1.79–7.16) and 2.34 (1.79–13.37), respectively. The genotype analysis of the +1664 C/T between SARS patients and control A group yielded different result with those between patients and control B group, when the control B group were compared, no difference of the genotype distribution can be detected. Genotype frequencies of +705 A/G, +1158 T/C or +1196 G/C SNPs were not significantly different between SARS patients and each of the two control groups.

Association between genotype frequencies of the 4 SNPs and the severity of SARS

SARS patients were then divided into two subgroups according to the severity of the disease: advanced subgroup (i.e., patients with moderate or advanced lung disease) and mild subgroup. Multiple regression models were re-established for each SNP, with age, sex and the source of infection hospital as covariates. Association with the severity of SARS infection was then estimated by comparing the genotype frequencies and allele frequencies of all the SNPs between the two groups of SARS patients. The final model building disclosed prominent associations between advanced disease with carrying +1664 C/T (CT and TT) genotype (P = 0.037). However, this was found not to be significant after Nyholt correction was applied to the analysis. Again, there were no significant differences in the genotype and allele distributions of the +705 A/G, +1158 T/C or +1196 G/C SNPs between those with mild disease and those with advanced disease (data not shown).

Haplotype analysis

Pairwise linkage disequilibrium (LD) analysis of the four SNPs showed strong LD among +705 A/G, +1158 T/C and +1196 G/C SNPs.

Table 1. The demographic characteristics of SARS patients and controls

|                   | SARS patients (n = 115) | Control A (n = 141) | Control B (n = 155) | P valuea | ORb (95% CI) | ORc (95% CI) | P valueb |
|-------------------|-------------------------|---------------------|---------------------|----------|-------------|-------------|----------|
| Ethnic (Han %)    | 100                     | 100                 | 100                 | 1        | 1           | 1           | 1        |
| Sex (male %)      | 32.5                    | 46.7                | 71.0                | 1        | 1           | 1           | 1        |
| Age (mean ± SD)   | 33.1 ± 11.7             | 31.6 ± 7.0          | 28.4 ± 11.8         | 1        | 1           | 1           | 1        |
| Health care workers (%) | 83 (72%) | 110 (78%) | 0 (0%) | 1 | 1 | 1 | 1 |
| Comorbidity (%)   | 10 (8.7%)               | 13 (9.2%)           | 10 (6.5%)           | 1        | 1           | 1           | 1        |

Table 2. Allele frequencies of the IL-12 RB1 705A/G, 1158T/C, 1196G/C and 1664 C/T SNPs in SARS patients and controls

| SNPs       | SARS (n = 115) | Control A (n = 141) | Control B (n = 155) | ORa (95% CI) | P valuea | ORb (95% CI) | P valueb |
|------------|----------------|---------------------|---------------------|-------------|----------|-------------|----------|
| +705 A/G   |                |                     |                     |             | 1        | 1           | 1        |
| A          | 131 (64.2)     | 137 (60.6)          | 186 (61.6)          | 1           | 1        | 1           | 1        |
| G          | 73 (35.8)      | 89 (39.3)           | 116 (38.4)          | 0.87 (0.89–1.09) | 0.224   | 0.91 (0.62–1.46) | 0.171   |
| +1158 T/C  |                |                     |                     |             | 1        | 1           | 1        |
| T          | 124 (64.6)     | 164 (65.6)          | 189 (63.0)          | 1           | 1        | 1           | 1        |
| C          | 68 (35.4)      | 86 (34.4)           | 111 (37.0)          | 1.10 (0.39–1.70) | 0.443   | 0.81 (0.56–2.41) | 0.525   |
| +1196 G/C  |                |                     |                     |             | 1        | 1           | 1        |
| G          | 139(62.6)      | 165(62.5)           | 190(63.3)           | 1           | 1        | 1           | 1        |
| C          | 83(37.4)       | 99(37.5)            | 110(36.7)           | 1.01 (0.79–1.71) | 0.829   | 1.06 (0.51–1.31) | 0.744   |
| +1664 C/T  |                |                     |                     |             | 1        | 1           | 1        |
| C          | 133 (70.7)     | 213 (80.7)          | 229 (76.3)          | 1           | 1        | 1           | 1        |
| T          | 55(29.3)       | 51(19.3)            | 71(23.7)            | 1.92 (1.11–6.06) | 0.044   | 1.35 (1.06–1.70) | 0.056   |

P-value and OR (95% CI) were calculated with the use of logistic regression models, adjusted with sex, age, comorbidity presence and infection source.

OR a Patients VS Control A ; ORb Patients VS Control B.

P valuea Patients VS Control A ; P valueb Patients VS Control B.

doi:10.1371/journal.pone.0002183.t001

Comorbidity (%) 10 (8.7%) 13 (9.2%) 10 (6.5%)

Health care workers (%) 83 (72%) 110 (78%) 0 (0%)

Sex (male %) 32.5 46.7 71.0

Ethnic (Han %) 100 100 100

P value 0.044 1.92 (1.11–6.06) 0.044 1.35 (1.06–1.70) 0.056

T 55(29.3) 51(19.3) 71(23.7) 1.92 (1.11–6.06) 0.044 1.35 (1.06–1.70) 0.056

C 133 (70.7) 213 (80.7) 229 (76.3) 1 1

G 139(62.6) 165(62.5) 190(63.3) 1 1

P = Odds ratio; CI = confidence interval;

P valuea Patients VS Control A ; P valueb Patients VS Control B.
doi:10.1371/journal.pone.0002183.t002
SNPs (D’ = 0.90–0.98) and modest LD value between +1664 C/T and one of the other three SNPs (D’ = 0.64–0.81), thus revealing two common haplotypes (A-T-G-C (705-1158-1196-1664) and G-C-C-T). To investigate if a particular haplotype constituted by these SNPs was associated with the disease, haplotype frequencies were estimated and association analysis was performed using multiple logistic regression with age, sex and infection source being the covariants. As shown in Table 4, the frequency of GCCT haplotype in SARS patients (26.6%) was significantly increased when compared to the control A group (11.1%), but when compared to the control B group, the proportions of this haplotype in the two groups were not different (26.6% in SARS patients vs. 22.3% in controls).

**Table 3. Genotype frequencies of IL-12 RB1 705A/G, 1158T/C, 1196G/C and 1664 C/T SNPs in SARS patients and controls groups**

| SNP       | SARS (n = 115) | Control A (n = 141) | Control B (n = 155) | OR* (95% CI) | P value* | ORb (95% CI) | P valueb |
|-----------|----------------|---------------------|---------------------|--------------|----------|--------------|----------|
| +A705G    |                |                     |                     |              |          |              |          |
| AA        | 41 (40.2)      | 43 (38.1)           | 59 (39.1)           | 1            |          |              |          |
| GA        | 49 (48.0)      | 51 (45.1)           | 68 (45.0)           | 1.26 (0.20–1.05) | 0.171    | 1.17 (0.95–4.91) | 0.223 |
| GG        | 12 (11.8)      | 19 (16.8)           | 24 (15.9)           | 0.76 (0.32–2.90) | 0.062    | 0.64 (0.35–3.14) | 0.194 |
| +T1158C   |                |                     |                     |              |          |              |          |
| TT        | 40 (41.7)      | 56 (44.8)           | 59 (39.3)           | 1            |          |              |          |
| TC        | 44 (45.8)      | 52 (41.6)           | 71 (47.3)           | 1.29 (0.94–3.44) | 0.105    | 0.90 (0.53–2.68) | 0.137 |
| CC        | 12 (12.5)      | 17 (13.6)           | 20 (13.3)           | 0.71 (0.39–3.97) | 0.219    | 0.84 (0.44–5.01) | 0.166 |
| +G1196C   |                |                     |                     |              |          |              |          |
| GG        | 44 (39.6)      | 53 (40.2)           | 59 (39.3)           | 1            |          |              |          |
| GC        | 52 (46.8)      | 59 (44.7)           | 72 (48.0)           | 1.19 (0.71–3.07) | 0.712    | 0.85 (0.25–6.10) | 0.221 |
| CC        | 15 (13.5)      | 20 (15.2)           | 19 (12.7)           | 0.86 (0.74–3.83) | 0.328    | 1.13 (0.39–6.95) | 0.417 |
| +C1664T   |                |                     |                     |              |          |              |          |
| CC        | 47 (50.0)      | 87 (65.9)           | 88 (58.7)           | 1            |          |              |          |
| CT        | 39 (41.5)      | 39 (29.5)           | 52 (34.7)           | 2.09 (1.90–7.16) | 0.020*   | 1.45 (1.16–2.78) | 0.047 |
| TT        | 8 (8.5)        | 6 (4.5)             | 10 (6.7)            | 2.34 (1.79–13.37) | 0.022*   | 1.47 (0.26–2.26) | 0.060 |

P-value and OR (95% CI) were calculated with the use of logistic regression models, adjusted with sex, age, comorbidity presence and infection source.

OR = Odds ratio; CI = confidence interval;
OR * Patients VS Control A ; ORb Patients VS Control B.
P value* Patients VS Control A ; P valueb Patients VS Control B.
*Significant P value after correction by Nyholt method
doi:10.1371/journal.pone.0002183.t003

**Table 4. Estimated frequencies of haplotypes constituted by 705A/G, 1158T/C, 1196G/C and 1664 C/T SNPs of IL-12 RB1 in SARS patients and controls**

| Haplotype | SARS patients N(%) | Control A N (%) | Control B N (%) | OR* (95% CI) | P value* | ORb (95% CI) | P valueb |
|-----------|---------------------|-----------------|-----------------|--------------|----------|--------------|----------|
| ATGC      | 111 (59.0)          | 131 (58.0)      | 182 (60.7)      | 1            |          |              |          |
| GCCT      | 50 (26.6)           | 25 (11.1)       | 67 (22.3)       | 2.31 (1.72–8.47) | 0.011*   | 1.14 (0.81–3.10) | 0.443 |
| GCCC      | 15 (7.9)            | 52 (23.0)       | 28 (9.3)        | 0.29 (0.07–0.63) | 0.017*   | 0.90 (0.13–1.97) | 0.602 |
| Others^c  | 12 (6.4)            | 18 (8.0)        | 23 (7.7)        | 0.76 (0.39–2.01) | 0.314    | 0.92 (0.44–4.19) | 0.580 |

P-value and OR (95% CI) were calculated with the use of logistic regression models, adjusted with sex, age, comorbidity presence and infection source.

OR = Odds ratio; CI = confidence interval;
*OR of Patients VS Control A ;
^OR of Patients VS Control B.
*Significant P value after correction by Nyholt method
doi:10.1371/journal.pone.0002183.t004

**Discussion**

IL-12R has previously been reported to be associated with infectious diseases such as tuberculosis, hepatitis B virus infection, and parvovirus infection [22–24], revealing its potential role of function in host defense against microbial infections. We genotyped 4 SNPs (+705A/G, +1158T/C, +1196G/C and +1664 C/T) that have been alleged to cause missense mutations of the IL-12RB1 gene in SARS patients, close contacts and healthy controls. These four SNPs (one novel) have been confirmed to cause missense variants in the extracellular coding sequence of the IL12RB1 gene. These four SNPs lie within 6.2-kb span of genomic DNA on chromosome 19p13.1. It is suggested that one or more of...
the four missense variants could affect the quality (or quantity) of the gene products and cause mild functional impairment in the receptor’s responsiveness to IL-12 [25]. The results show that individuals with 1664 C/T (CT) and (TT) genotype were at increased risk of susceptibility to SARS infection. When only severe patients were considered, the significance disappeared, in comparison with the mild patients. We also estimated the frequencies of IL-12 RB1 haplotypes, which composed of 4 polymorphic alleles, and identified risk haplotype (GCCT) that might confer genetic susceptibility to SARS infection. In agreement with this finding, the +1664 C/T (T) allele was among the risk haplotypes GCCT, whereas the alternative C allele was among the protective haplotype (GCCG). These findings support the association between IL12B1 polymorphism and SARS infection, but not necessary the disease outcome in Chinese population.

It is interesting to note that these associations only exist when close contacts were used as a control group. When healthy blood donors were used as controls, no association could be detected. We reasoned that genetic difference between the two control groups might partly account for the distinct observations with regard to SARS susceptibility, i.e. close contacts might be more immunogenetically resistant to SARS infection than healthy controls. In this case, close contacts might serve as more suitable controls healthy individuals, who had never been exposed to SARS-CoV. It’s as well intriguing that the pattern of polymorphism in +1664 C/T in SARS patients deviated slightly from Hardy-Weinberg equilibrium. As noted in the previous study[26], detection of HW disequilibrium at SNP loci in the case sample could be an indicator that a disease/susceptibility gene is within the region. There are also other possibilities indicated, like that a pseudo-SNP is present, DNA contamination, or a genotyping error, however, these latter possibilities are unlikely since we have duplicated the genotyping assay for all the samples with ambiguous results through sequencing. This also can be argued from the observed perfect adherence to Hardy-Weinberg disequilibrium from control group. The chance of subgroup is minor, since all the subjects were Chinese Han population without consanguineous relationship. Taken together, we suggested this deviation was from the correlation between genetic variant and disease, instead of false association.

SARS pathogenesis is less well understood, yet it is a vital issue in the disease management. It has been suggested that genetic variations of the host and/or the virus may account for the individual difference in the severity of the disease. Studies have addressed some of the host genes that might play a role in disease development [5,7]. However, all the available studies have failed to take viral factor(s) into consideration. These studies thus cannot exclude the possible false association caused by the differentiated viral adaption in humans. The SARS patients in the current study were mostly health care workers in two SARS-designated hospitals. Epidemiological investigations have clearly defined detailed transmission among those patients, showing each of the group came from one super spread chain arising from one infection source. In the multiple logistic analysis, we used the infection source as one of the covariants, and by doing so, we could technically exclude the potential confounding effect that might be caused by viral factor(s). Advanced age and presence of comorbidity are other two factors that might influence the disease susceptibility[3,4], which were excluded from potential confounding by multiple variants analysis.

It should be mentioned not all of the subjects were genotyped due to the inadequacy of DNA samples. Especially for the +C1664T SNP, different percentages of genotypes were missing from SARS, Control A, and Control B groups (18.2%, 6.4% and 3.2% respectively). One can reasonably argue there was another SNP that accounted for the increased fraction of subjects without the defined genotypes in the SARS patient group. It can also be argued that the significant SNPs actually are not functional variants of the IL-12RB1 protein, but instead it is presumably in linkage disequilibrium with a potential functional variant(s) in other loci of the gene. Presently 15 coding, nonsynonymous SNPS are listed in the Entrez database dbSNP, out of a total of 274 known human SNPs for IL12RB1, however, the genotyping for other SNPs in small group of the current population showed MAF (minor allele frequency) of less than 5% (unpublished data). We thus propose the lack of a complete analysis of the SNPS in this gene can pose no severe damage to the study. Still we could not formally exclude additional possible causal variation(s) elsewhere in the gene.

The sequencing of the exon and the promoter regions of the IL12RB1 gene from the SARS patient cohort could be helpful in identifying other SNPs which could alter the gene expression level. It would also be warranted to examine whether the same association is observed in other ethnic groups. On the other hand, a relatively small sample size inevitably resulted in limitations of the power to detect significant association in disease outcome. As such, the negative results on SNPs for disease outcome revealed in this study do not necessarily exclude their association with SARS.

In one previous study, marked elevation of IL-12 in plasma of SARS patients had been observed for at least 2 weeks after disease onset[27]. Since IL-12 can induce the production of IFN-γ and other Th1 cytokines with suppression of the Th2 pathway [28,29], the observed early elevation of IL-12 could be causative of the SARS-CoV-induced activation of Th1 cells and NK cells, release of chemokines such as IL-6, and results in pulmonary inflammation [30]. One could then hypothesize that decreased IL-12R activity might predispose to infection but protect from severe disease manifestations. However, the data presented here appear to suggest that IL-12R activity is required for protection from severe disease, although the association between genetic polymorphisms and severe disease was no longer significant after multiple test correction was applied to the analysis. Therefore the actual role of IL12 in the protection from or susceptibility to severe disease still need more evidence from animal experiments.

In summary, our data support the association between IL-12 RB1 polymorphism and SARS. These genetic variations might predispose individuals to SARS infection by diminishing receptor responsiveness to IL-12, leading to partial dysfunction of interferon-γ-mediated immunity. Further genetic and biologic studies of these genetic variants could also render valuable insights into SARS susceptibility and pathogenesis.

Acknowledgments
We thank all of the patients and the health-care workers who participated in the present study.

Author Contributions
Conceived and designed the experiments: WC WL. Performed the experiments: FT WL MF FZ PX HY. Analyzed the data: WC FT WL ZX HY HL. Contributed reagents/materials/analysis tools: MW PZ. Wrote the paper: WC FT WL FZ ZX HL.
References

1. Peiris JS, Guan Y, Yuen KY (2004) Severe acute respiratory syndrome. Nat Med 10: S83–97.
2. Lau YL, Peiris JS (2005) Pathogenesis of severe acute respiratory syndrome. Curr Opin Immunol 17: 404–410.
3. Booth CM, Matukas LM, Tonlinson GA, Rachlis AR, Rose DB, et al. (2003) Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA 289: 2001–2009.
4. Chan JW, Ng CK, Chan YH, Mok TY, Lee S, et al. (2003) Short-term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS). Thorax 58: 686–689.
5. Chiu RW, Tang NL, Hui DS, Chung GT, Chim SS, et al. (2004) ACE2 gene polymorphisms do not affect outcome of severe acute respiratory syndrome. Clin Chem 50: 1603–1606.
6. Itoyama S, Keicho N, Hijkata M, Qay T, Phi NC, et al. (2005) Identification of an alternative 5'-untranslated exon and new polymorphisms of angiotensin-converting enzyme 2 gene: lack of association with SARS in the Vietnamese population. Am J Med Genet A 136: 52–57.
7. Itoyama S, Keicho N, Qay T, Phi NC, Long HT, et al. (2004) ACE1 polymorphism and progression of SARS. Biochem Biophys Res Commun 325: 1124–1129.
8. Ip WK, Chan KH, Law HK, Tso GH, Kong EK, et al. (2005) Mannose-binding lectin in severe acute respiratory syndrome coronavirus infection. J Infect Dis 191: 1697–1704.
9. Zhang H, Zhou G, Zhai L, Yang H, Zhai Y, et al. (2005) Association between mannose-binding lectin gene polymorphisms and susceptibility to severe acute respiratory syndrome coronavirus infection. J Infect Dis 192: 1353–1361.
10. He J, Feng D, de Vlas SJ, Wang H, Fontanet A, et al. (2006) Association of SARS susceptibility with single nucleic acid polymorphisms of OAS1 and MxA genes: a case-control study. BMC Infect Dis 6: 106–112.
11. Chong WP, Ip WK, Tso GH, Ng MW, Wong WH, et al. (2006) The interferon gamma gene polymorphism -874 A/T is associated with severe acute respiratory syndrome. BMC Infect Dis 6: 82–96.
12. Ip MW, Ng CK, Chong WP, Lee LW, Law HK, et al. (2007) The association of RANTES polymorphism with severe acute respiratory syndrome in Hong Kong and Beijing Chinese. BMC Infect Dis 7: 50.
13. Chan KY, Ching JC, Xu MS, Cheung AN, Yip SP, et al. (2007) Association of ICAM3 genetic variant with severe acute respiratory syndrome. J Infect Dis 196: 271–280.
14. Trinchieri G (1998) Proinflammatory and immunoregulatory functions of interleukin-12. Int Rev Immunol 16: 355–396.
15. Dorman SE, Holland SM (2000) Interferon-gamma and interleukin-12 pathway defects and human disease. Cytokine Growth Factor Rev 11: 321–333.
16. Cameron MJ, Ran I, Xu L, Dansheh A, Bemerjo-Martin JF, et al. (2007) Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome. J Virol; 81: 8692–8706.
17. Chua AO, Chizzonite R, Desai BR, Truitt TP, Nones P, et al. (1994) Expression cloning of a human IL-12 receptor component: a new member of the cytokine receptor superfamily with strong homology to gap130. J Immunol 153: 128–136.
18. Persky DH, Cahuler U, Chizzonite RA, Gately MK (1995) IL-12 receptors and receptor antagonists. Res Immunol 146: 439–444.
19. WHO (2003) Case definitions for surveillance of severe acute respiratory syndrome (SARS). Geneva: World Health Organization, (http://www.who.int/csr/sars/casedefinition/en/). Accessed June 2003.
20. Lee HW, Lee HS, Kim DK, Ko DS, Hah SK, et al. (2005) Lack of an Association between Interleukin-12 Receptor B1 Polymorphisms and Tuberculosis in Koreans. Respiration 72: 365–368.
21. Nyholt DR (2004) A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet 74: 765–769.
22. Fieschi C, Dupuis S, Catherinot E, Feinberg J, Bastamante J, et al. (2005) Low penetrance, broad resistance, and favorable outcome of Interleukin 12 receptor B1 deficiency: medical and immunological implications. J Exp Med 197: 527–535.
23. Caragol I, Rasgall M, Fieschi C, Feinberg J, Larrosa MN, et al. (2003) Clinical tuberculosis in 2 of 3 siblings with interleukin-12 receptor B1 deficiency. Clin Infect Dis 37: 302–306.
24. Staretz-Haham O, Melamed R, Lifshitz M, Porat N, Fieschi C, et al. (2003) Interleukin-12 receptor B1 deficiency presenting as recurrent Salmonella infection. Clin Infect Dis 37: 137–140.
25. Sukai T, Matsumoto M, Aoki M, Nosaka K, Mitsuha H (2001) Missense mutation of interleukin-12 receptor B1 chain-encoding gene is associated with impaired immunity against Mycobacterium avium complex infection. Blood 97: 2688–2694.
26. Leaf SM (2005) Detection of genotyping errors and pseudo-SNPs via deviations from Hardy-Weinberg equilibrium. Genet Epidemiol 29: 204–214.
27. Wong CK, Lam CW, Wu AK, Ip WK, Lee NL, et al. (2004) Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol. 136: 95–103.
28. Kennedy MK, Picha KS, Shanebeck KD, Anderson DM, Grabstein KH (1994) Interleukin-12 regulates the proliferation of Th1, but not Th2 or Th0, clones. Eur J Immunol 24: 2271–2278.
29. Manetti R, Gerosa F, Giuliani MG, Biagiotti R, Parronchi P, et al. (1994) Interleukin 12 induces stable priming for interferon gamma (IFN-gamma) production during differentiation of human T helper (Th) cells and transient IFN-gamma production in established Th2 cell clones. J Exp Med 179: 1273–1283.
30. Veen Beeth K, Van Gucht S, Pensaert M (2002) In vivo studies on cytokine involvement during acute viral respiratory disease of swine: troublesome but rewarding. Vet Immunol Immunopathol 87: 161–168.